...
首页> 外文期刊>International journal of molecular medicine >The combinatory effects of PPAR-γ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells
【24h】

The combinatory effects of PPAR-γ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells

机译:PPAR-γ激动剂和survivin抑制对膀胱癌细胞癌干样表型和细胞增殖的联合作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Strategies for peroxisome proliferator-activated receptor (PPAR) activation or survivin inhibition have potential for cancer therapy. However, whether the combination of these two approaches can be developed as a rational regimen with enhanced efficiency in the inhibition of tumor cells remains to be determined. In this study, the combinatory effect of PPAR-γ agonist and survivin inhibition on bladder cancer cells was investigated. T24 and 5637 cells were treated with 15d-PGJ2 to determine whether 15d-PGJ2 had an inhibitory effect. Cell viability and proliferation were analyzed and efficiency of survivin siRNAs was assessed using western blot analysis. The results showed that, in the human bladder cancer cell lines T24 and 5637, the natural PPAR-γ ligand 15d-PGJ2 significantly decreased cell proliferation and loci formation. The increase in the proportion of apoptotic cells was observed in the cells 48?h after 15d-PGJ2 treatment. Furthermore, 15d-PGJ2 substantially inhibited the levels of stemness-related genes in these cells. The ability of sphere formation was markedly suppressed in the cells treated with 15d-PGJ2. More importantly, the downregulation of survivin with siRNAs significantly enhanced the 15d-PGJ2-mediated induction of cell apoptosis and inhibition of sphere formation. Accordingly, we also found that survivin inhibition significantly enhanced 15d-PGJ2-induced production of reactive oxygen species (ROS) in bladder cancer cells. Taken together, these findings suggest that the combination of 15d-PGJ2 and survivin inhibition play a potentially role in the therapeutical manipulation of bladder cancer.
机译:过氧化物酶体增殖物激活受体(PPAR)激活或survivin抑制的策略具有潜在的癌症治疗潜力。然而,这两种方法的组合是否可以发展为具有增强的抑制肿瘤细胞效率的合理方案尚待确定。在这项研究中,研究了PPAR-γ激动剂和survivin抑制作用对膀胱癌细胞的联合作用。用15d-PGJ2处理T24和5637细胞以确定15d-PGJ2是否具有抑制作用。分析细胞活力和增殖,并使用蛋白质印迹分析评估survivin siRNA的效率。结果表明,在人膀胱癌细胞系T24和5637中,天然PPAR-γ配体15d-PGJ2显着降低了细胞增殖和基因座形成。 15d-PGJ2处理后48?h细胞中凋亡细胞比例增加。此外,15d-PGJ2实质上抑制了这些细胞中与茎相关的基因的水平。在用15d-PGJ2处理的细胞中,球形形成的能力明显受到抑制。更重要的是,用siRNA下调survivin可以显着增强15d-PGJ2介导的细胞凋亡诱导作用,并抑制球的形成。因此,我们还发现存活蛋白抑制显着增强了膀胱癌细胞中15d-PGJ2诱导的活性氧(ROS)的产生。两者合计,这些发现表明15d-PGJ2和survivin抑制的组合可能在膀胱癌的治疗操作中发挥潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号